ArticleEJNMMI radiopharmacy and chemistry2017
Article in EJNMMI radiopharmacy and chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 90 citations in OpenAlex.
- Investigation of aBMC cancer · 2026Article
- Sc(III) Complexes of Pyclen Derivative Ligands as Probes for Hypoxia: Synthesis, Chemical Characterization,Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- An overview of the role of radionuclides in targeted cancer treatment: application of biomarkers for patient selection and developments to improve treatment efficacy.Frontiers in oncology · 2025Review
- Production of high purityEJNMMI radiopharmacy and chemistry · 2024Article
- Comparison of the dosimetry of scandium-43 and scandium-44 patient organ doses in relation to commonly used gallium-68 for imaging neuroendocrine tumours.EJNMMI physics · 2024Article
- Target Development towards First Production of High-Molar- ActivityPharmaceuticals (Basel, Switzerland) · 2024Article
- Nuclear Cross-Section of Proton-Induced Reactions on EnrichedPharmaceuticals (Basel, Switzerland) · 2023Article
- Scandium Radioisotopes-Toward New Targets and Imaging Modalities.Molecules (Basel, Switzerland) · 2023Review
- RUNX3 regulates the susceptibility against EGFR-targeted non-small cell lung cancer therapy usingBMC cancer · 2023Article
- Cryomilling of Isotope-Enriched Ti Powders for HIVIPP Deposition to Manufacture Targets for Nuclear Cross Section Measurement.Materials (Basel, Switzerland) · 2023Article
- Engineering a modularEJNMMI research · 2023Article
- Current State ofCurrent radiopharmaceuticals · 2023Review
- Cutting edge rare earth radiometals: prospects for cancer theranostics.EJNMMI radiopharmacy and chemistry · 2022Review
- Advances in PSMA theranostics.Translational oncology · 2022Article
- Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.Theranostics · 2022Review
- Cyclotron production and radiochemical purification of terbium-155 for SPECT imaging.EJNMMI radiopharmacy and chemistry · 2021Article
- Production of scandium radionuclides for theranostic applications: towards standardization of quality requirements.EJNMMI radiopharmacy and chemistry · 2021Review
- Production, Collection, and Purification ofACS omega · 2020Article
- Image quality analysis ofEJNMMI physics · 2020Article
- A Step-by-Step Guide for the Novel Radiometal Production for Medical Applications: Case Studies withMolecules (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiotheragnostics makes use of the same molecular targeting vectors, labeled either with a diagnostic or therapeutic radionuclide, ideally of the same chemical element. The matched pair of scandium radionuclides,
methods
resultsUp to 2 GBq
conclusionThe production of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.